Open access · US-GOV
via ClinicalTrials.gov Clinical trial
A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
Authors not listed
MediBeacon · 2025
Abstract
The objective of this study is to evaluate the safety and image quality of the investigational dye, MB-102, compared to the control dye (fluorescein sodium) in healthy and diseased eyes using fluorescent angiography for retinal vascular disease diagnosis and monitoring.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2025). A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium. <em>MediBeacon</em>. https://clinicaltrials.gov/study/NCT04008121
Vancouver
Anonymous. A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium. MediBeacon. 2025.
BibTeX
@misc{anon2025APilot,
title = {A Pilot Study to Assess the Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium},
author = {Anonymous},
journal = {MediBeacon},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Ionis Pharmaceuticals, Inc. 2024
Open access · US-GOV
A Phase 1b Study to Assess the Safety, Tolerability, and Pharmacokinetics of ION269 in Adults With Down Syndrome (Hero Study)
The Hong Kong Polytechnic University 2027
Open access · US-GOV
The Evidence-based Nurse-led Risk-informed Intervention for Community-based Healthy Ageing (ENRICH) Study: A Mixed-methods Feasibility Study of a Nurse-led Model of Care for Social Frailty in Philippine Primary Care
GeroScience 2024
Preprint · OA
GrimAge is elevated in older adults with mild COVID-19 an exploratory analysis
Alpha Cognition, Inc 2026
Open access · US-GOV
RESOLVE: A Phase 4, Open-label Study to Assess the Effect of Zunveyl on Safety and Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Adults With Mild to Moderate Alzheimer's Disease
Shanghai Greenvalley Pharmaceutical Co., Ltd. 2014
Open access · US-GOV
Phase III Study of Sodium Oligo-mannurarate (GV-971) Capsule on Mild to Moderate Alzheimer Disease
Green Valley (Shanghai) Pharmaceuticals Co., Ltd. 2021
Open access · US-GOV